Research context
A long-acting amylin analogue under investigation for metabolic indications.
Regulatory note: Verify local laws, product approval and professional guidance before any human use. This profile is not a recommendation for use.
Metabolic research
Cagrilintide
A long-acting amylin analogue under investigation for metabolic indications.
68 connected records39 graded citations0 external identifiers
Evidence map
Claims linked to original records.
Evidence levels describe study design. They do not by themselves establish safety or effectiveness.
Petersen J, Merrild C, Holm SK, Kurgan N, Hassan S, Mathiesen CV, Börchers S, Svendsen C, D'Anna S, Andersen NR, Klein AB, Fritzen AM, Deshmukh AS, Pers TH, Clemmensen C
Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.
pubmed
Chen D, Ma B, Sun H, Zhang J, Gong L, Wang W, Liu Z, Zha H, Du S, Chen M, Sun W, Guo Q, Cao Y, Li Y
Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.
pubmed 2026
Moiz A, Filion KB, Samuels AE, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.
pubmed
Khan BW, Agha SA, Qamar I, Khattak MH, Rehman A, Qazi TI, Siddiqui SA, Zeeshan N, Khan UZ, Bibi H, Khan MF, Khan HW, Mian AM, Rafay MA
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.
pubmed
Sanchez-Navarro MJ, Zhang C, Schmidt HD, Hayes MR
Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
pubmed
Fischer SL, Borner T
Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs.
pubmed 2026
Yaseen M, Ameer A, Ali Z, Jamali JA, Kumar A, Basit Ali Siddiqui M, Kumari P, Hassaan M, Nanwani P, Abdul Basit M, Lohana N, Qureshi R, Tesfaye M
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.
pubmed 2026
Busetto L, Contreras CO, Christensen MH, Garvey TW, Horn DB, McGowan B, Miller CP, Schnecke V, le Roux CW
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
pubmed 2026
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the...
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
clinicaltrials 2025
This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that...
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
clinicaltrials 2024
The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment...
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
clinicaltrials 2026
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are...
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
clinicaltrials 2023
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during...
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
clinicaltrials 2022
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once...
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
clinicaltrials 2023
This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. Participants will either get CagriSema, a dummy medicine or semaglutide. Which treatment participants get is decided...
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
clinicaltrials 2023
This study is being done to look at how well a study medicine called CagriSema helps people with diabetes lower their blood sugar. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants...
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
clinicaltrials 2026
Shao C, Lin H, Yu J, Chen H, Ren Y, Ren J, Zeng Y, Wu Y, Bai H, Zhang Q, Xiao X
Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.
pubmed 2026
This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that...
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
clinicaltrials 2024
This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In...
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
clinicaltrials 2025
This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema...
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
clinicaltrials 2024
This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine. Participants...
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
clinicaltrials 2024
This trial is being done to look at the safety and effect of combining cagrilintide and NNC0480-0389 in people living with overweight and obesity compared to taking cagrilintide alone. In one period participants will get two medicines: cagrilintide and NNC0480-0389. In the other period, participants...
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese
clinicaltrials 2026
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may...
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
clinicaltrials 2024
Shao C, Lin H, Yu J, Chen H, Ren Y, Ren J, Zeng Y, Wu Y, Bai H, Zhang Q, Xiao X · Diabetes, metabolic syndrome and obesity : targets and therapy
Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.
pmc 2026
Alhazmi A, le Roux CW · Diabetes, obesity & metabolism
Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.
pmc 2026
Busetto L, Contreras CO, Christensen MH, Garvey TW, Horn DB, McGowan B, Miller CP, Schnecke V, le Roux CW · Diabetes, obesity & metabolism
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
pmc 2026
Li C, Lin C, Cai X, Lv F, Yang W, Ji L · Obesity (Silver Spring, Md.)
Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.
pmc 2026
Lewis JE, Montaner M, Nuzzaci D, James-Okoro PP, Harada N, Inagaki N, Dodson WS, Knerr PJ, Douros JD, Gribble FM, Reimann F · Nature metabolism
Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism.
pmc 2026
Yaseen M, Ameer A, Ali Z, Jamali JA, Kumar A, Basit Ali Siddiqui M, Kumari P, Hassaan M, Nanwani P, Abdul Basit M, Lohana N, Qureshi R, Tesfaye M · Annals of medicine and surgery (2012)
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.
pmc 2026
Dos Santos D, Castanheira da Silva A, Miranda F · European Psychiatry
The Overlooked Role of Psychiatrists in Obesity Management: A Multidisciplinary Perspective.
pmc 2026
· American Chemical Society (ACS)
Development of Cagrilintide, a Long-Acting Amylin Analogue
crossref
Q. Yuan, L. Zhao, Y. Gu · Worldwide Protein Data Bank
A combined Cryo_EM structure of Cagrilintide-AMY1R-Gs complex
crossref 2025
L. Zhao, Y. Gu, Q. Yuan · Worldwide Protein Data Bank
A combined cryo_EM structure of Cagrilintide-CTR-Gs complex
crossref 2025
Zsofia Hevesi, Tibor Harkany · Springer Science and Business Media LLC
Cellular loci for cagrilintide action identified
crossref 2026
· Wiley
Review for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"
crossref 2026
· Wiley
Review for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"
crossref 2026
Introduction and Objective: Cagrilintide is a long-acting amylin analogue currently in clinical development for the treatment of obesity, acting as a dual amylin and calcitonin receptor (CTR) agonist. While it produces robust body weight loss in humans, its effects are attenuated in mice, highlighting gaps...
2458-P: Arcuate Hypothalamic Circuits Mediate Acute Cagrilintide-Induced Feeding in Mice
crossref 2026
J. Cao, M.J. Belousoff, D.L. Wootten, P.M. Sexton, R.M. Johnson · Worldwide Protein Data Bank
Human Amylin2 Receptor in Complex with Gs and Cagrilintide
crossref 2024
Chen D, Ma B, Sun H, Zhang J, Gong L, Wang W, Liu Z, Zha H, Du S, Chen M, Sun W, Guo Q, Cao Y, Li Y · BMJ medicine
Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.
pmc 2026
Connected data hub
Records with source provenance.
Reviewed records carry an admin-reviewed badge. Automated records link back to the provider for independent checking.
Clinical Trial
43 recordsclinicaltrialsAdmin reviewed
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested...
clinicaltrialsAdmin reviewed
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity....
clinicaltrialsAdmin reviewed
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight
The purpose of this clinical study is to compare 2 different versions cagrilintide and see how these work in people living with excess body weight. Participant will get either cagrilintide B or cagrilintide D injections. Which treatment participant...
clinicaltrialsAdmin reviewed
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema...
clinicaltrialsAdmin reviewed
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity
The study is testing cagrilintide, a study medicine, to understand how it affects food intake and appetite in people with overweight or obesity. Participants will receive either cagrilintide or placebo, and which treatment participants get is decided by...
clinicaltrialsAdmin reviewed
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity
This clinical study is testing two versions of the study medicine cagrilintide. The purpose of the study is to compare these two versions to understand their effects in participants with overweight or obesity. Participants will receive either cagrilintide...
clinicaltrialsAdmin reviewed
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
The purpose of this clinical study is to look into how study medicines CagriSema (cagrilintide and semaglutide), cagrilintide, and semaglutide affects muscle health in people with excess body weight and slightly higher than normal blood sugar as they...
clinicaltrialsAdmin reviewed
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese
This trial is being done to look at the safety and effect of combining cagrilintide and NNC0480-0389 in people living with overweight and obesity compared to taking cagrilintide alone. In one period participants will get two medicines: cagrilintide...
clinicaltrialsAdmin reviewed
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
This study is being done to look at how well a study medicine called CagriSema helps people with diabetes lower their blood sugar. In this study the sponsor will compare two version of CagriSema injected by two different...
clinicaltrialsAdmin reviewed
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
This study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still being tested in studies and is not yet available for doctors to prescribe....
clinicaltrialsAdmin reviewed
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their blood sugar and body weight. The study has 2 parts: in the...
clinicaltrialsAdmin reviewed
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema...
clinicaltrialsAdmin reviewed
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get...
clinicaltrialsAdmin reviewed
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which...
clinicaltrialsAdmin reviewed
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
In this study we will be looking into how CagriSema influences metabolism (the process by which food is used to supply energy for the body) compared to a diet. CagriSema is a new investigational medicine. CagriSema cannot yet...
clinicaltrialsAdmin reviewed
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second...
clinicaltrialsAdmin reviewed
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
In this study we will investigate how the medicine cagrilintide affects bone health in women after menopause with obesity during weight loss, compared to treatment with placebo (the dummy medicine with no active substances) and semaglutide. The purpose...
clinicaltrialsAdmin reviewed
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment...
clinicaltrialsAdmin reviewed
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has...
clinicaltrialsAdmin reviewed
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human...
clinicaltrialsAdmin reviewed
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
This study will compare the blood levels of cagrilintide and semaglutide when the same dose is given in two different versions of CagriSema. CagriSema is a medicine that combines two medicines called cagrilintide and semaglutide. It is still...
clinicaltrialsAdmin reviewed
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine...
clinicaltrialsAdmin reviewed
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which...
clinicaltrialsAdmin reviewed
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes
This study will look at how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes (T2D). CagriSema is a new investigational medicine that combines two medicines called cagrilintide and semaglutide. Doctors...
clinicaltrialsAdmin reviewed
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In...
clinicaltrialsAdmin reviewed
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to...
clinicaltrialsAdmin reviewed
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to...
clinicaltrialsAdmin reviewed
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
This study will look at how CagriSema affects the blood levels of atorvastatin and warfarin. The study will look at the levels of warfarin and atorvastatin in the blood before the participant starts taking CagriSema and if this...
clinicaltrialsAdmin reviewed
A Study of How CagriSema Works on Appetite in People With Excess Body Weight
Part A: The study will look at participants appetite and energy intake and also look at the mechanisms of brain associated with appetite and food intake. Participants will not get any medicine and will be in a group...
clinicaltrialsAdmin reviewed
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to...
clinicaltrialsAdmin reviewed
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight
This research study tests if CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight. Participant will either get CagriSema (active medicine) or placebo (a dummy medicine), which has no effect on...
clinicaltrialsAdmin reviewed
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed...
clinicaltrialsAdmin reviewed
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors....
clinicaltrialsAdmin reviewed
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two...
clinicaltrialsAdmin reviewed
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. Participants will either get CagriSema, a dummy medicine or...
clinicaltrialsAdmin reviewed
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week. The study medicine will be...
clinicaltrialsAdmin reviewed
A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants
The study tests if treatment with cagrilintide delays the transmission of electrical signals in the heart compared to treatment with placebo. To confirm the sensitivity of the methodology, the drug moxifloxacin is also compared to a placebo in...
clinicaltrialsAdmin reviewed
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has...
clinicaltrialsAdmin reviewed
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they...
clinicaltrialsAdmin reviewed
A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body
The study is divided into two parts - Part A and Part B. Cagrilintide in combination with semaglutide, is under development for weight management. In the development of cagrilintide, it is important to see if liver function influences...
clinicaltrialsAdmin reviewed
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is...
clinicaltrialsAdmin reviewed
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
This study looks at how well a new medicine called cagrilintide works together with semaglutide on blood sugar levels in people with type 2 diabetes compared to cagrilintide alone or semaglutide alone. Before a new medicine can be...
clinicaltrialsAdmin reviewed
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity
This study will compare two different ways of giving cagrilintide and semaglutide for treating overweight and obesity. The medicines will either be given together in 1 injection or as 2 separate injections. The aim of the study is...
Open Access Article
8 recordspmcAutomated import
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
Busetto L, Contreras CO, Christensen MH, Garvey TW, Horn DB, McGowan B, Miller CP, Schnecke V, le Roux CW · Diabetes, obesity & metabolism
pmcAutomated import
Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.
Shao C, Lin H, Yu J, Chen H, Ren Y, Ren J, Zeng Y, Wu Y, Bai H, Zhang Q, Xiao X · Diabetes, metabolic syndrome and obesity : targets and therapy
pmcAutomated import
Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.
Chen D, Ma B, Sun H, Zhang J, Gong L, Wang W, Liu Z, Zha H, Du S, Chen M, Sun W, Guo Q, Cao Y, Li Y · BMJ medicine
pmcAutomated import
Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.
Alhazmi A, le Roux CW · Diabetes, obesity & metabolism
pmcAutomated import
Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.
Li C, Lin C, Cai X, Lv F, Yang W, Ji L · Obesity (Silver Spring, Md.)
pmcAutomated import
Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism.
Lewis JE, Montaner M, Nuzzaci D, James-Okoro PP, Harada N, Inagaki N, Dodson WS, Knerr PJ, Douros JD, Gribble FM, Reimann F · Nature metabolism
pmcAutomated import
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.
Yaseen M, Ameer A, Ali Z, Jamali JA, Kumar A, Basit Ali Siddiqui M, Kumari P, Hassaan M, Nanwani P, Abdul Basit M, Lohana N, Qureshi R, Tesfaye M · Annals of medicine and surgery (2012)
pmcAutomated import
The Overlooked Role of Psychiatrists in Obesity Management: A Multidisciplinary Perspective.
Dos Santos D, Castanheira da Silva A, Miranda F · European Psychiatry
Publication
9 recordspubmedAutomated import
Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs.
Fischer SL, Borner T
pubmedAutomated import
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
Busetto L, Contreras CO, Christensen MH, Garvey TW, Horn DB, McGowan B, Miller CP, Schnecke V, le Roux CW
pubmedAutomated import
Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.
Shao C, Lin H, Yu J, Chen H, Ren Y, Ren J, Zeng Y, Wu Y, Bai H, Zhang Q, Xiao X
pubmedAutomated import
Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.
Chen D, Ma B, Sun H, Zhang J, Gong L, Wang W, Liu Z, Zha H, Du S, Chen M, Sun W, Guo Q, Cao Y, Li Y
pubmedAutomated import
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.
Yaseen M, Ameer A, Ali Z, Jamali JA, Kumar A, Basit Ali Siddiqui M, Kumari P, Hassaan M, Nanwani P, Abdul Basit M, Lohana N, Qureshi R, Tesfaye M
pubmedAutomated import
Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.
Petersen J, Merrild C, Holm SK, Kurgan N, Hassan S, Mathiesen CV, Börchers S, Svendsen C, D'Anna S, Andersen NR, Klein AB, Fritzen AM, Deshmukh AS, Pers TH, Clemmensen C
pubmedAutomated import
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.
Moiz A, Filion KB, Samuels AE, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ
pubmedAutomated import
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.
Khan BW, Agha SA, Qamar I, Khattak MH, Rehman A, Qazi TI, Siddiqui SA, Zeeshan N, Khan UZ, Bibi H, Khan MF, Khan HW, Mian AM, Rafay MA
pubmedAutomated import
Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
Sanchez-Navarro MJ, Zhang C, Schmidt HD, Hayes MR
Scholarly Work
8 recordscrossrefAutomated import
Cellular loci for cagrilintide action identified
Zsofia Hevesi, Tibor Harkany · Springer Science and Business Media LLC
crossrefAutomated import
2458-P: Arcuate Hypothalamic Circuits Mediate Acute Cagrilintide-Induced Feeding in Mice
Introduction and Objective: Cagrilintide is a long-acting amylin analogue currently in clinical development for the treatment of obesity, acting as a dual amylin and calcitonin receptor (CTR) agonist. While it produces robust body weight loss in humans, its...
crossrefAutomated import
Review for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"
· Wiley
crossrefAutomated import
Review for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"
· Wiley
crossrefAutomated import
A combined Cryo_EM structure of Cagrilintide-AMY1R-Gs complex
Q. Yuan, L. Zhao, Y. Gu · Worldwide Protein Data Bank
crossrefAutomated import
A combined cryo_EM structure of Cagrilintide-CTR-Gs complex
L. Zhao, Y. Gu, Q. Yuan · Worldwide Protein Data Bank
crossrefAutomated import
Human Amylin2 Receptor in Complex with Gs and Cagrilintide
J. Cao, M.J. Belousoff, D.L. Wootten, P.M. Sexton, R.M. Johnson · Worldwide Protein Data Bank
crossrefAutomated import
Development of Cagrilintide, a Long-Acting Amylin Analogue
· American Chemical Society (ACS)
Live discovery
Latest research signals
Live results from PubMed, ClinicalTrials.gov and UniProt. These may not yet have been reviewed or stored in the Data Hub.
Recent PubMed records
Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats.PMID 42951207 · 2026 Oct 28Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.PMID 42935221 · 2026 Oct 27CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.PMID 42890523 · 2026Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3).PMID 42838477 · 2026 Oct 6Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.PMID 42812898 · 2026Registered clinical studies
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseNCT06409130 · COMPLETEDA Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboNCT06131372 · COMPLETEDA Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightNCT07605052 · COMPLETEDReviewed UniProt records
Responsible use of information
Fitzbio provides educational and research reference material. It does not diagnose, prescribe or replace advice from a qualified healthcare professional.